News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (303 of 347). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 347). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (33 of 347). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 347 items have one.
Millions take fish oil for brain health. A two-year study found no benefit
A surprising two-year clinical trial found that fish oil supplements successfully delivered omega-3s to the brain but failed to improve memory or protect against Alzheimer's-related brain shrinkage. …
Alzheimer's blood biomarker tracks brain amyloid similarly across racial groups, study finds
A large global study provides new evidence supporting the use of blood biomarkers in an Alzheimer's clinical trial to screen for elevated brain amyloid levels among potential participants who are cognitively unimpaired. …
Read at Medical Xpress → Archived copy (13 Oct 2026), Internet ArchiveClinical trial tests AI-assisted medication device for older adults with memory loss
Marianne Blake has lived in the same home for nearly half a century. She plays bridge regularly, drives to her hair appointments and, at 88 years old, enjoys her independence.
Read at Medical Xpress →Trial testing cholesterol-lowering med as potential Alzheimer’s intervention
NewAmsterdam Pharma has dosed the first participant in a large mid-stage clinical trial assessing the safety and effectiveness of its cholesterol-lowering treatment candidate obicetrapib as a potential aid for people with preclinical Alzheimer’s disease. …
Read at Alzheimer's News Today →Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3 program.
Free to read? Not known for this outlet.
Read at Fierce Biotech → Archived copy (25 Sep 2026), Internet ArchivePill form of semaglutide fails to slow Alzheimer's in large trial
A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer's disease, drugmaker Novo Nordisk announced on Nov. 24.
Why it matters: A pill form of semaglutide failed to slow Alzheimer's disease progression in a large trial, Novo Nordisk announced on Nov. 24.
Read at Medical Xpress → Archived copy (6 Jan 2026), Internet ArchiveAlzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release
Novo Nordisk's EVOKE and EVOKE+ Phase 3 trials of oral semaglutide in more than 3,800 people with early symptomatic Alzheimer's did not meet the primary endpoint of significantly slowing disease progression, despite improving some Alzheimer's-related biomarkers. Novo Nordisk ended its Alzheimer's trials for semaglutide, including the injectable version.
Why it matters: A high-profile failure for the theory that GLP-1 weight-loss drugs could treat Alzheimer's, dampening near-term hopes for repurposing this popular drug class for dementia.
Read at Alzheimer's Association → Archived copy (30 Jul 2026), Internet ArchiveJ&J's Novel Alzheimer's Drug Fails in Key Trial, Dimming Hopes for a Hot Target
Johnson & Johnson terminated its mid-stage trial of posdinemab, a tau-targeting antibody, after an early analysis showed it was not outperforming placebo in slowing Alzheimer's progression.
Why it matters: A setback for the broader strategy of targeting tau protein rather than amyloid, a drug class also being pursued by Biogen, UCB, and Voyager Therapeutics.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (1 Mar 2026), Internet ArchiveRoche Presents New Insights in Alzheimer's Disease Research at AAIC (Trontinemab Phase Ib/IIa Data)
Roche's trontinemab, an antibody engineered to cross the blood-brain barrier more efficiently, cleared amyloid below the positivity threshold in 91% of participants at the highest dose after 28 weeks, with ARIA-E occurring in fewer than 5% of participants. Roche plans Phase 3 trials (TRONTIER 1 and 2) starting later in 2025.
Why it matters: Suggests a next-generation amyloid antibody could clear plaques faster and with a better safety profile than currently approved drugs, if Phase 3 results confirm early findings.
Free to read? Not known for this outlet.
Read at Roche → Archived copy (25 Jul 2026), Internet ArchiveAlzheon's Alzheimer's Pill Fails in Phase III Trial
Alzheon's oral drug valiltramiprosate missed the primary endpoint in its 325-patient APOLLOE4 Phase 3 trial of early Alzheimer's patients with two copies of the APOE4 gene, though a prespecified mild cognitive impairment subgroup showed larger cognitive and functional benefits.
Why it matters: Another setback for a non-antibody, oral approach to Alzheimer's treatment, though the positive subgroup signal could still support a narrower regulatory path.
Free to read? Not known for this outlet.
Read at Clinical Trials Arena → Archived copy (17 Jun 2026), Internet ArchiveSenolytic therapy shows subtle impact on age-related bone health in women
An NIA-funded clinical trial investigating whether senolytics could improve bone health in older women had just subtle results.
Why it matters: An NIA-funded clinical trial investigating whether senolytics could improve bone health in older women had just subtle results.
Read at NIH National Institute on Aging → Archived copy (7 Jul 2025), Internet ArchiveFollow new items in a feed reader: Atom feed.